Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Philogen SpA ( (IT:PHIL) ) is now available.
Philogen S.p.A. reported a significant financial turnaround in 2024, achieving record profits with revenues tripling from the previous year. The company is advancing its product pipeline with key developments including the ongoing evaluation of Nidlegy™ for melanoma by EMA, promising results in radiopharmaceuticals, and a new collaboration with Sun Pharma for Fibromun. These advancements underscore Philogen’s strengthened position in the biotechnology sector and its commitment to innovative cancer treatments.
More about Philogen SpA
Philogen S.p.A. is a biotechnology company focused on the development of innovative therapies for cancer treatment. The company is involved in research and development, with a market focus on cancer immunotherapy and radiopharmaceuticals.
YTD Price Performance: -2.11%
Average Trading Volume: 290
Technical Sentiment Signal: Sell
Current Market Cap: €580.5M
For a thorough assessment of PHIL stock, go to TipRanks’ Stock Analysis page.